organization · Reporting owner
Aquilo Capital, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Spero Therapeutics, Inc.
Report date September 22, 2022 · Filed September 26, 2022
Jointly reported with Aquilo Capital Management, LLC
Section 16 reporting ended · disclosed 2022-09-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectSee Footnotes | 3,985,719 |
Reported balance
After 2022-09-22 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-09-22 · Sale · Disposed 1,335,512 · Balance 3,985,719 F1: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2: Aquilo Capital, LP owns 2,176,470 of the 3,985,719 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP sold 1,335,512 shares in this transaction on 09/22/2022. |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectSee Footnotes | 3,419,435 |
Reported balance
After 2022-09-22 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2022-09-22 · Sale · Disposed 566,284 · Balance 3,419,435 F1: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F3: Aquilo Capital, LP owns only 2,176,470 of the 3,419,435 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not sell any of the 566,284 shares sold in this transaction on 09/22/2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein.
F2: Aquilo Capital, LP owns 2,176,470 of the 3,985,719 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP sold 1,335,512 shares in this transaction on 09/22/2022.
F3: Aquilo Capital, LP owns only 2,176,470 of the 3,419,435 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not sell any of the 566,284 shares sold in this transaction on 09/22/2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2022 Filed Sep 26, 2022 19:32 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock, $0.001 par value | 566,284 | $2.25 | $1,274,308.89 |
DisclosureSEC source: 0001591986-22-000018 · primary_doc.xml · nonDerivative · entry 2 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,419,435 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F3 · balance_after: Aquilo Capital, LP owns only 2,176,470 of the 3,419,435 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not sell any of the 566,284 shares sold in this transaction on 09/22/2022. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| September 22, 2022 Filed Sep 26, 2022 19:32 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock, $0.001 par value | 1,335,512 | $2.25 | $3,005,302.65 |
DisclosureSEC source: 0001591986-22-000018 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,985,719 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns 2,176,470 of the 3,985,719 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP sold 1,335,512 shares in this transaction on 09/22/2022. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 20:13 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 39,727 | $5.24 | $207,970.85 |
DisclosureSEC source: 0001591986-22-000015 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,321,231 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP only owns 3,511,982 of the 5,321,231 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP purchased 39,727 shares in this transaction on 4/26/2022. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 19:51 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 16,885 | $8.79 | $148,392.13 |
DisclosureSEC source: 0001591986-22-000014 · primary_doc.xml · nonDerivative · entry 2 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,281,504 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F3 · balance_after: Aquilo Capital, LP only owns 3,472,255 of the 5,281,504 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 16,885 shares purchased in this transaction on 03/30/2022. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 19:51 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 33,115 | $8.79 | $291,027.87 |
DisclosureSEC source: 0001591986-22-000014 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,264,619 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP only owns 3,472,255 of the 5,264,619 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP purchased 33,115 shares in this transaction on 3/30/2022. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:23 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 8,006 | $7.63 | $61,053.76 |
DisclosureSEC source: 0001591986-22-000013 · primary_doc.xml · nonDerivative · entry 2 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,231,504 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F3 · balance_after: Aquilo Capital, LP only owns 3,439,140 of the 5,231,504 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 8,006 shares purchased in this transaction on 03/14/2022. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:23 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 15,702 | $7.63 | $119,743.45 |
DisclosureSEC source: 0001591986-22-000013 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,223,498 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP only owns 3,439,140 of the 5,223,498 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP purchased 15,702 shares in this transaction on 3/14/2022. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 20:52 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 15,104 | $9.53 | $143,930.55 |
DisclosureSEC source: 0001591986-22-000011 · primary_doc.xml · nonDerivative · entry 2 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,207,796 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F3 · balance_after: Aquilo Capital, LP owns only 3,423,438 of the 5,207,796 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 15,104 shares purchased in this transaction on 02/28/2022. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 20:52 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 29,729 | $9.53 | $283,296.56 |
DisclosureSEC source: 0001591986-22-000011 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,192,692 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns 3,423,438 of the 5,192,692 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP purchased 29,729 shares in this transaction on 2/28/2022. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:24 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 14,828 | $9.24 | $137,038.89 |
DisclosureSEC source: 0001591986-22-000010 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,162,963 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns 3,393,709 of the 5,162,963 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP purchased 14,828 shares in this transaction on 2/18/2022. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 01:26 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 125,000 | $11.59 | $1,448,262.50 |
DisclosureSEC source: 0001591986-22-000004 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,148,135 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 5,148,135 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 125,000 shares purchased in this transaction on 01/31/2022. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 22:12 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 1,599 | $10.89 | $17,418.07 |
DisclosureSEC source: 0001591986-22-000003 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,023,135 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 5,023,135 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 1,599 shares purchased in this transaction on 01/24/2022. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 18:07 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 48,488 | $12.41 | $601,963.97 |
DisclosureSEC source: 0001591986-22-000002 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,021,536 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 5,021,536 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 48,488 shares purchased in this transaction on 01/18/2022. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:43 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 8,867 | $12.93 | $114,608.64 |
DisclosureSEC source: 0001591986-22-000001 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,973,048 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,973,048 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 8,867 shares purchased in this transaction on 01/10/2022. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 19:46 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 125,000 | $15.75 | $1,969,025.00 |
DisclosureSEC source: 0001691902-22-000001 · primary_doc.xml · nonDerivative · entry 3 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,964,181 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F4 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,964,181 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 125,000 shares purchased in this transaction on 12/31/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 19:46 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 50,000 | $15.77 | $788,610.00 |
DisclosureSEC source: 0001691902-22-000001 · primary_doc.xml · nonDerivative · entry 2 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,839,181 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F3 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,839,181 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 50,000 shares purchased in this transaction on 12/30/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| December 29, 2021 Filed Jan 3, 2022 19:46 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 75,493 | $14.64 | $1,105,262.82 |
DisclosureSEC source: 0001691902-22-000001 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,789,181 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,789,181 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 75,493 shares purchased in this transaction on 12/29/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 21:47 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 150,000 | $17.53 | $2,630,175.00 |
DisclosureSEC source: 0001591986-21-000016 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,713,688 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,713,688 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 150,000 shares purchased in this transaction on 10/29/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 15:36 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 134,543 | $18.65 | $2,509,173.13 |
DisclosureSEC source: 0001591986-21-000015 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,563,688 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,563,688 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 134,543 shares purchased in this transaction on 09/30/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 23:21 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 2,156 | $18.49 | $39,872.42 |
DisclosureSEC source: 0001591986-21-000014 · primary_doc.xml · nonDerivative · entry 2 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,429,145 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F3 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,429,145 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 2,156 shares purchased in this transaction on 09/14/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 23:21 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 44,210 | $18.56 | $820,674.65 |
DisclosureSEC source: 0001591986-21-000014 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,426,989 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,426,989 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 44,210 shares purchased in this transaction on 09/13/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 21:21 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 24,749 | $18.50 | $457,792.15 |
DisclosureSEC source: 0001591986-21-000013 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,382,779 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,382,779 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 24,749 shares purchased in this transaction on 09/09/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 21:42 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 48,645 | $18.93 | $920,660.13 |
DisclosureSEC source: 0001591986-21-000012 · primary_doc.xml · nonDerivative · entry 2 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes. Disclosed balance after: 4,358,030 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F3 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,358,030 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 48,645 shares purchased in this transaction on 08/31/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 21:42 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 44,042 | $17.87 | $786,858.78 |
DisclosureSEC source: 0001591986-21-000012 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,309,385 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,309,385 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 44,042 shares purchased in this transaction on 08/30/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| August 27, 2021 Filed Aug 27, 2021 21:11 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 13,957 | $16.88 | $235,531.35 |
DisclosureSEC source: 0001591986-21-000011 · primary_doc.xml · nonDerivative · entry 2 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,265,343 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F3 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,265,343 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 13,957 shares purchased in this transaction on 08/27/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 21:11 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 22,982 | $16.55 | $380,322.22 |
DisclosureSEC source: 0001591986-21-000011 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,251,386 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,251,386 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 22,982 shares purchased in this transaction on 08/26/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| August 24, 2021 Filed Aug 24, 2021 20:28 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 40,170 | $16.28 | $653,794.87 |
DisclosureSEC source: 0001591986-21-000010 · primary_doc.xml · nonDerivative · entry 3 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,228,404 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F4 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,228,404 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 40,170 shares purchased in this transaction on 08/24/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:28 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 137,835 | $16.33 | $2,251,341.76 |
DisclosureSEC source: 0001591986-21-000010 · primary_doc.xml · nonDerivative · entry 2 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,188,234 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F3 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,188,234 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 137,835 shares purchased in this transaction on 08/23/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:28 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock, $0.001 par value | 221,190 | $14.86 | $3,286,905.52 |
DisclosureSEC source: 0001591986-21-000010 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,050,399 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F2 · balance_after: Aquilo Capital, LP owns only 3,378,881 of the 4,050,399 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 221,190 shares purchased in this transaction on 08/20/2021. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 18:35 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock, $0.001 Par Value | 3,000 | $21.74 | $65,215.20 |
DisclosureSEC source: 0001591986-21-000003 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,829,209 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 04, 2021 Filed Feb 4, 2021 23:46 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock, $0.001 Par Value | 34,144 | $18.99 | $648,254.57 |
DisclosureSEC source: 0001591986-21-000001 · primary_doc.xml · nonDerivative · entry 4 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,832,209 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 23:46 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock, $0.001 Par Value | 29,354 | $18.98 | $557,100.76 |
DisclosureSEC source: 0001591986-21-000001 · primary_doc.xml · nonDerivative · entry 3 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,866,353 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 23:46 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock, $0.001 Par Value | 22,841 | $18.99 | $433,771.15 |
DisclosureSEC source: 0001591986-21-000001 · primary_doc.xml · nonDerivative · entry 2 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,895,707 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 23:46 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock, $0.001 Par Value | 13,661 | $19.24 | $262,860.86 |
DisclosureSEC source: 0001591986-21-000001 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,918,548 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:43 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock, $0.001 par value | 250,000 | $18.81 | $4,703,225.00 |
DisclosureSEC source: 0001591986-20-000019 · primary_doc.xml · nonDerivative · entry 2 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 3,932,209 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:43 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock, $0.001 par value | 14,933 | $18.62 | $278,034.54 |
DisclosureSEC source: 0001591986-20-000019 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,182,209 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| November 09, 2020 Filed Nov 11, 2020 00:14 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock, $0.001 par value | 125,900 | $13.77 | $1,734,071.06 |
DisclosureSEC source: 0001591986-20-000016 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,197,142 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo,the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo,the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| November 06, 2020 Filed Nov 7, 2020 01:48 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock, $0.001 par value | 5,000 | $13.77 | $68,873.50 |
DisclosureSEC source: 0001591986-20-000015 · primary_doc.xml · nonDerivative · entry 3 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,323,042 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| November 05, 2020 Filed Nov 7, 2020 01:48 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock, $0.001 par value | 96,600 | $13.98 | $1,350,332.76 |
DisclosureSEC source: 0001591986-20-000015 · primary_doc.xml · nonDerivative · entry 2 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,328,042 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| November 04, 2020 Filed Nov 7, 2020 01:48 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock, $0.001 par value | 72,500 | $14.26 | $1,033,741.25 |
DisclosureSEC source: 0001591986-20-000015 · primary_doc.xml · nonDerivative · entry 1 Aquilo Capital Management, LLC · CIK 0001591986 · 10% owner Aquilo Capital, L.P. · CIK 0001491371 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,424,642 F1 · security: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. F1 · ownership.nature: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.